BRCA gene mutations: What every Indian woman should know
A clear guide to what BRCA1 and BRCA2 mutations actually mean for your risk, and what to do if you’re wondering whether testing is right for you
This content is for informational purposes only and does not constitute medical advice. Genetic risk is personal and complex, and any testing or risk-reduction decision should be made with a qualified doctor or genetic counsellor. As of 2026.
Most people have heard of BRCA in passing, usually connected to a celebrity who chose preventive surgery after testing positive. What gets lost in that headline version is what the gene actually does, why a mutation matters so much, and what a positive result actually means for day-to-day decisions. None of it is as frightening, or as simple, as it’s often made out to be.
This guide is built to walk through it properly.
What are BRCA1 and BRCA2 gene mutations?
BRCA1 and BRCA2 are genes that produce proteins responsible for repairing damaged DNA inside cells. Everyone has two copies of each gene, one inherited from each parent, and in most people both copies work normally.
The name is a bit misleading. BRCA stands for Breast Cancer, but the genes themselves don’t cause cancer. Quite the opposite. When they’re working properly, they actually protect against it by fixing DNA damage before it can turn into something dangerous. Problems start when one copy carries a harmful change, sometimes called a pathogenic variant, that stops it from doing this job properly.
What happens when a BRCA gene is mutated?
Having one working copy of BRCA1 or BRCA2 is usually enough to keep a cell’s repair system functioning, since only one normal copy is needed. The risk comes from what happens over a lifetime. If that second, healthy copy also gets damaged or lost in a particular cell, which happens naturally over time, that cell loses its DNA repair ability entirely and becomes far more likely to turn cancerous.
This is why BRCA-related cancers tend to develop earlier in life than typical breast or ovarian cancer, and why they can affect either breast, or lead to a second cancer in the future, more often than cancers unrelated to an inherited mutation.
How much does a BRCA mutation actually raise cancer risk?
This is the number most people actually want, and it’s worth seeing next to the general population risk for context.
Group | Lifetime breast cancer risk | Lifetime ovarian cancer risk |
General population (average woman) | About 13 percent | Under 2 percent |
BRCA1 mutation carrier | 55 to 72 percent | 39 to 58 percent |
BRCA2 mutation carrier | 45 to 69 percent | 13 to 29 percent |
Source. National Cancer Institute, BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet.
A few things are worth sitting with here. A BRCA mutation doesn’t guarantee cancer. Plenty of carriers never develop it. But it changes the odds substantially, and it changes the age at which cancer is more likely to show up, often well before the age routine screening typically starts. BRCA2 mutations also raise risk for men, including breast cancer and prostate cancer, and both genes are linked to a smaller increase in pancreatic cancer risk.
How common are BRCA mutations in Indian women?
This is where the picture gets genuinely important for an Indian audience, because the numbers here don’t simply mirror Western data.
A diagnostic lab study of 395 Indian breast cancer patients tested between 2021 and 2023 found BRCA mutations in 29.1% of cases, a notably high rate. Among high-risk families specifically, one of the largest Indian analyses, covering just over a thousand families, found BRCA mutations accounted for 85% of the inherited mutations identified. A separate North Indian study found a 30% prevalence of BRCA mutations among breast and ovarian cancer patients who met testing criteria, and prevalence rose to 75% among women under 40 who also had a first-degree relative with breast or ovarian cancer.
Reported prevalence across India swings quite a bit, from as low as 2.9% to as high as 38%, depending on the study population and how families were selected for testing. That range reflects real gaps in India’s genetic testing infrastructure as much as biology, since access to high-quality testing and counselling still varies a lot by region.
What all of this adds up to is fairly direct. BRCA mutations are not rare among Indian women who develop breast or ovarian cancer at a young age or who have a strong family history, and testing based on family history alone risks missing a meaningful number of carriers.
Who should consider BRCA testing?
Genetic testing isn’t recommended for everyone, and that’s actually reassuring rather than restrictive. It’s aimed at people whose personal or family history suggests a meaningfully higher chance of carrying a mutation. Situations that typically warrant a conversation about testing include:
- Breast cancer diagnosed before age 50, especially before 40.
- Triple-negative breast cancer, particularly under age 60.
- Cancer in both breasts, in the same person, at any age.
- Ovarian, fallopian tube, or primary peritoneal cancer at any age.
- A close relative, parent, sibling, or child, with a known BRCA mutation.
- Multiple relatives on the same side of the family with breast, ovarian, pancreatic, or prostate cancer.
- Male breast cancer anywhere in the family.
- Ashkenazi Jewish ancestry combined with any personal or family history of these cancers.
Having one of these factors doesn’t automatically mean a mutation will be found. It means the chance is high enough that testing is genuinely worth discussing with a doctor, rather than something to seek out purely out of general anxiety.
What does the testing process actually involve?
BRCA testing itself is straightforward for the patient. It’s usually done from a blood or saliva sample, and results typically take a couple of weeks. What matters far more than the mechanics of the swab is what happens around it.
Pre-test counselling helps set expectations, walking through what a positive, negative, or uncertain result would actually mean before the sample is even taken. This matters because BRCA results aren’t always a clean yes or no. Some tests come back with a “variant of uncertain significance,” a change in the gene whose effect on cancer risk isn’t yet clearly established. That result isn’t the same as a negative test, and it isn’t the same as a positive one either. It needs its own conversation.
Post-test counselling is just as important, particularly for a positive result, since it opens up decisions about surveillance, prevention, and whether other family members should consider testing too. Our precision oncology guide goes into more detail on how genetic and molecular testing more broadly is used to guide personalised treatment decisions.
What are the options if you test positive?
A positive BRCA result is information, not a diagnosis. It opens up a set of choices, and different people reasonably choose differently based on age, family plans, and personal comfort with risk.
Enhanced surveillance is one path, typically meaning earlier and more frequent screening, often combining mammography with breast MRI starting well before the standard screening age. For more on how screening decisions are generally made, see our guide on breast cancer.
Risk-reducing surgery is another option some carriers choose, including preventive mastectomy or removal of the ovaries and fallopian tubes, usually considered once childbearing is complete. These are significant decisions, and they’re never the only acceptable choice.
Chemoprevention, medication that lowers breast cancer risk, is an option for some carriers who prefer not to pursue surgery.
If cancer has already developed, BRCA status directly shapes treatment too. BRCA-mutated cancers often respond particularly well to a class of targeted drugs called PARP inhibitors, and to platinum-based chemotherapy, which is part of why testing matters even after a diagnosis has already been made, not just before one.
What gets in the way of BRCA testing in India?
It’s worth being honest about this rather than glossing over it. Cost is a real barrier, and testing prices vary considerably across the country. Genetic counselling capacity is another gap. In much of India, pre- and post-test counselling is handled by the treating oncologist rather than a dedicated genetic counsellor, simply because there aren’t enough trained genetic counsellors to go around yet.
None of this means testing isn’t worthwhile. It means the conversation about whether, when, and where to test is worth having directly with an oncologist who can walk through the practical realities alongside the medical ones.
The takeaway
A BRCA mutation changes the odds, but it doesn’t decide the outcome. For Indian women specifically, the data suggests these mutations are more common than many people assume, particularly among those diagnosed young or with a strong family history, which makes the decision to test, or not to test, a genuinely informed one rather than a guess.